Mr. Leung has over 15 years’ experience in the life science and finance industries. Currently, he is the Chairman of Uni-Bio Science Group and also serves as Director in both Great Bay Bio and DotBio. He has broad experience in sourcing, evaluating and executing new growth opportunities, supporting the execution and alliance management of 8 deals, including the in-licensing of next generation oncology, inflammation and respiratory drugs from MNCs. Mr. Leung also has extensive experience in the finance industry where he worked in healthcare investment banking in Merrill Lynch and a family office, helping evaluated IPO opportunities for multiple companies across the US and PRC. Up to date, Mr. Leung has led and successfully raised over USD60M across multiple of his ventures. Mr. Leung was awarded the prestigious honour of World Outstanding Young Leaders Award from Yazhou Zhoukan in 2016, Entrepreneur of the Year from CAPITAL in 2017, Young Industrialist Awards of Hong Kong in 2020, and Gen.T Social Impact and Leader of Tomorrow 2021.
Mr. Leung is currently a Chartered Financial Analyst and a member of The Hong Kong Society of Financial Analysts. He was also elected the Vice Chairman of Pharmaceutical & Chemical group of the Federation of Hong Kong Industries (FHKI). Mr. Leung holds a BSc in Biochemistry from Imperial College London, an MSc in Pharmacology from the University of Oxford, and EMBA from Tsinghua-INSEAD. In addition, he holds a Professional Diploma in Corporate Governance & Directorship from the HongKong Institute of Directors.
Mr. Chen Dawei has more than 20 years of experience in enterprise management, capital market and merger and acquisition. He has set up and invested in companies, and has accumulated abundant operational experience in both domestic and foreign capital markets. Over the years, Mr. Chen had taken the roles as Chairman, Chief Executive Office, Executive Director and Vice Chairman of China Everbright Water Limited (formerly known as HanKore Environment Tech Group Limited), which is listed on the Main Board of the Singapore Exchange Limited and the sole water business platform of China Everbright Group Ltd. Currently, he is the Executive Partner of a Chinese equity investment fund and the Chairman of a Singapore capital management company. He has earned an Executive Master’s degree in Business Administration (major in China-America Finance) from Peking University, and the Master's degree in Business Administration from the National University of Singapore
Mr. Zhao Zhi Gang has over 20 years of experience in corporate finance and audit practice with various publicly listed companies and PricewaterhouseCoopers in the U.S. and in China. Previously, Mr. Zhao held senior financial positions in a number of healthcare companies including Chief Financial Officer of Simcere Pharmaceutical Group, one of the largest pharmaceutical companies in China, where he led the public listing of the company in the U.S. and Kingmed Centre for Clinical Laboratories, a leading company in China that provides comprehensive laboratory testing services. In addition, he was an investment consultant with Beijing International Trust and Investment Company. Mr. Zhao has also held other senior financial positions or directorships including independent director of Zuoan Fashion Ltd., Borqs Beijing Limited and Sun New Media Group Limited. Mr. Zhao holds a bachelor’s degree in Economics from the Peking University and a master’s degree in Professional Accounting from the University of Hartford. Mr. Zhao is a U.S. certified public accountant and a fellow of the American Institute of Certified Public Accounts.
Mr. Tony Yau attained his bachelor’s degree with first class honours in Accountancy from The Hong Kong Polytechnic University. He is a certified public accountant (CPA) of the Hong Kong Institute of Certified public Accountants. Mr. Yau has deep insight in corporate management and accumulated over 20 years of experience from the capital market and investment banks. He offered consultancy services to many large-scale and recognizable IPO and M&A projects. He is currently the Chief Executive Officer and a director of Futec International Holdings Limited and HeungKong Financial Group Limited. Prior to that, he was a Managing Director of Global Investment Banking of Deutsche Bank and had spent over 11 years leading the consumer sector business origination and execution in Asia. From August 2000 to May 2006, Mr. Yau was the vice president of the investment banking department of BNP Paribas Capital (Asia Pacific) Limited.
Mr. Qingshan Ma attained two bachelor’s degrees from Peking University, majoring in Finance at Guanghua School of Management and Electronic Commerce at School of Electronics Engineering and Computer Science. He is holding the qualification of the Chartered Financial Analyst (CFA). He also participated in the Insead EMBA project held by Tsinghua University. Prior to his appointment, Mr. Ma has provided services at various consulting firms and practiced management for over 16 years, including provision of management consulting services for 15 Fortune 500 companies and a number of listed public companies and fast-growing enterprises, and also once serving as consulting director of KPMG Advisory (China) Limited and Accenture (China) Co., Ltd.. Leveraging on his years of practical experience in data management, corporate KPI management, business optimization and digitization for companies.
Mr. Paul Chow has more than 26 years of experience in financial management, auditing and tax planning in accounting firms. He holds a Master Degree in Business Administration from Heriot-Watt University and he is a fellow member of Hong Kong Institute of Certified Public Accountants (since 1994). He is also a fellow member of the Association of Chartered Certified Accountants since 1997, the Taxation Institute of Hong Kong since 1999 and has been a certified Tax Advisor since 2010.
Mr. Ren has more than 24 years of management experience. He was the Deputy Secretary General and Executive Director of the board of directors of the China Association for International Friendly Contact for 10 years, primarily responsible for affairs relating to the Chinese Government and arranging meetings for international governmental agencies, political parties, other commercial organization and senior Chinese governmental authorities. He has served as a director and a senior manager in several companies from 1993 to the present day.. Previously, Mr. Ren was the senior advisor of the Beijing office of CIGNA Corporation, a global health insurance service company from 1997 to 1999 primarily responsible for government relation affairs. Prior to that, Mr. Ren was also the General Manager of 蓋洛普（中國）咨詢有限公司 (unofficial english translation being Gallup (China) Consulting Limited) which mainly provides market research and polling services. Gallup Inc. is a joint-venture set up by a Chinese investor as well as Gallup Inc., a global performance-management consulting company at the time. Mr. Ren was primarily responsible for assisting the start of its operations in China from 1993 to 1996. Currently, he serves as an executive director of Carta Group Limited, a company principally engaged in international public relations and governmental affairs consultancy service. He obtained a Master Degree in Economics from Anhui University in 1990.
Ph.D. in Fermentation Engineering, South China University of Technology, has more than 30 years of experience in biotechnology and the development of GMP and GLP facilities, as well as developing new drugs and clinical research projects, and has been with Uni-Bio Science for more than 20 years. He has won the Science and Technology Progress Award of the Chinese Academy of Sciences and has a number of patents.
Mr. An has over 16 years experience in the pharmaceutical industry. Prior to Uni-Bio Science, Mr. An was responsible for the sales and marketing in Tasly Pharmaceutical Group (600535.SH), a renowned A-share listed company. Mr. An has broad experience in sales channel sourcing, sales forecasting and sales executing, leading the commercialization of several important products, capturing the largest market share in several drug sectors. Mr. An holds a BSc in Science from Henan Agricultural University, an MSc in Business Administration from Nankai University.
Dr. Li, Senior Engineer; Postdoctoral fellow, University of Dentistry and Medicine, New Jersey, USA and Ph.D in Biochemistry and Molecular Biology of Professor Jiancong Shen (Member of Chinese Academy of Sciences) of State Key Laboratory of Supramolecular Structure and Materials of Jilin University. In 2009, she studied in Advanced Biotechnology and Medicine Research Center in New Jersey, USA, where she worked in the laboratory of Professor Masayori Inouye ("National Famous Professor in USA"), engaged in frontier research in Medicine such as Toxin-Antitoxin System. She also participated in the "NIH", "NSF" and other international leading healthcare research projects such as cancer in the United States. She has More than 10 years of experience in drug development in oncology and endocrinology as well as Clinical Trial Application (CTA) and New Drug Application (NDA). She ever served as Former Head of Bio-pharmaceutical Research Institute of Yangtze River Pharmaceutical Group, and she has published more than 20 articles and patents in international SCI journals.
Mr. Zhao, Senior engineer, has a Master of Pharmacognosy from Northeast Forestry College and a MBA from Harbin University of Technology. He had six municipal science and technology progress awards. Mr. Zhao worked at the Harbin Pharmaceutical Group and served the Head of Clinical Research and Development. He had been developed the Drugs that brought billions of sales for the company. Mr. Zhao has 5 years of pharmaceutical R & D experience and more than 10 years of clinical R & D experience in listed companies. He is familiar with GCP and ICH-GCP, with a solid clinical background, also has rich experience on clinical research and development.
Ms. Tian graduated in Chengdu University of Technology, and holds diploma for the national HR legal affairs Director and HR senior Manager. Ms. Tian has 13 years experience in HR and administration, with rich experience in recruitment, training, employee relationship and dispute.
Mr. Du, graduated in Capital University of Economics and Business, holds the accountant qualification issued by the Ministry of Human Resources and Social Security and the Ministry of Finance of China, and is a member of the China Tax Accountants Association. He has more than 17 years of financial management experience, especially in the biopharmaceutical industry.